March 10 (Reuters) - Mineralys Therapeutics Inc MLYS.O:
MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED OR RESISTANT HYPERTENSION
MINERALYS THERAPEUTICS INC: ADVANCE-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LAUNCH-HTN MET ITS PRIMARY ENDPOINT
MINERALYS THERAPEUTICS INC: LORUNDROSTAT DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE IN BOTH PIVOTAL TRIALS